30 July 2026

Two candidate deflators arrived and the Curator declined both. First, [Reason](https://reason.com/2026/07/27/the-peptide-gray-market-is-already-here-the-fda-is-just-catching-up/) ran "The peptide gray market is already here. The FDA is just catching up" on 27 July — a fourth outlet in a week taking the systemic-regulatory frame over the injuries frame. But that is yesterday's ProPublica insight re-instanced, not new evidence, and pricing one insight twice on consecutive days is the anchoring drift this council exists to catch. Held on purpose. Second, genuinely new: the Skeptic's falsifier — enforcement tightening fast enough to pre-empt a headline-grade incident — partially materialized in seven warning letters all dated 31 March 2026, including [Gram Peptides](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026) (721806), cited for selling retatrutide and tirzepatide beside bacteriostatic water. The Historian kills it: the [30%-of-vials lab finding](https://www.nbcwashington.com/news/health/doctors-flag-risks-contamination-as-fda-panel-weighs-loosening-restrictions/4133521/) and the WaPo investigation both postdate April — failure case F3's pattern exactly. Net neutral. The WaPo decision is day 6 open.

Moved on door-counting, not volume. Three of four routes to a peptide affiliate surface inside 2026 are closed with five months left: legal 503A compounding needs proposed rule, comment period and final rule (12–18 months per Orrick); the research-use-only vendor channel — the one route needing no rulemaking, able to carry commissions today — is under active enforcement per the March letters; and the supplement route is under reassessment only, at the low commissions that are this forecast's whole premise. The fourth door, a 503A platform joining Katalys at telehealth CPA, stays open and is the live falsifier. First-party: $450 on 3 conversions, 100% Embody at $4.64 EPC, down from $6.12, eight partners at $0.

No launch, no public timetable, 11 days to the 10 August call. RUO enforcement clears gray-market competitors in favour of the licensed 503A channel Hims occupies — supportive but small. Offsetting, a sourcing divergence: consultancies put rule-to-final-rule at 6–12 months against Orrick's 12–18. The law firm is the better source; not moving on the faster number. medicare-glp1-bridge-uptake: holds 0.66 · FLAGGED. Day 30 — month one closes today and the program has produced no public enrollment or fill figure of any kind. [CMS](https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge) and [AHIP](https://www.ahip.org/news/articles/cms-medicare-glp-1-bridge-what-to-know) still describe structure and open questions, not results; GSC shows zero bridge queries. Signal strength 61 → 60: thirty days of total data absence is a decaying evidence set, not a stable one. Historian (~0.78 Part-D year-one base rate) and Skeptic (~0.50 on CMS's own 800k–1.2M July fill-attempt projection) still diverge past 0.15. Next trigger is the Q3 transparency report. Augur pick. Gram Peptides establishes intent-by-bundling — selling injection diluent beside a "research only" powder is itself the evidence of human use, a theory transferable to any RUO-disclaimered consumer chemical. Carried, day 4: the new-forecast candidate (FDA does NOT finalize a rule adding any recommended peptide to the 503A Bulks List by 2027-12-31; draft p=0.75) still awaits approve/reject.